Summary: Brad Burge of MAPS speaks with Psychedelics Today about Phase 3 trials of MDMA-assisted psychotherapy for PTSD, the FDA’s Expanded Access program, and the Zendo Project’s psychedelic peer support services.
Originally appearing here.
In this Episode, Joe interviews Brad Burge, Director of Strategic Communications at MAPS. In this episode they discuss the Phase 3 Trial for MDMA Assisted Therapy, contradictions and Expanded Access.
